Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Arachnoiditis, a circumstance characterized by irritation of the arachnoid membrane surrounding the spinal wire, is prompted by market factors associated with its prevalence and occurrence. The demand for treatments and cures is directly impacted by the range of people stricken by this circumstance, prompting pharmaceutical groups to be conscious of studies and development. The style of treatment modalities available in the marketplace drastically shapes the landscape of arachnoiditis management. Pharmaceutical companies developing novel tablets, ache control solutions, and rehabilitation healing procedures cater to the numerous needs of patients. The efficacy, safety, and accessibility of those remedies impact market increase and patient consequences.
The regulatory environment notably impacts the arachnoiditis market. Stringent approval approaches, regulatory compliance, and adherence to ethical requirements form the market dynamics. Companies navigating the regulatory landscape efficaciously are better placed to convey new remedies to the market and deal with unmet clinical desires. The normal healthcare infrastructure, which includes the supply of specialized medical centers and know-how, influences the arachnoiditis market. Access to comprehensive healthcare facilities and skilled healthcare specialists enhances patient care and contributes to the market's typical increase. Patient focus and training tasks impact the demand for arachnoiditis treatments. Increased cognizance among sufferers, caregivers, and healthcare specialists ends in early analysis and intervention. Companies investing in academic programs contribute to an extra knowledgeable patient population, positively influencing market trends.
Economic factors, including healthcare spending and coverage insurance, play a crucial role within the arachnoiditis market. Affordability and compensation policies impact patients' entry to treatments. Market gamers should remember monetary variables to ensure the accessibility of their merchandise in diverse healthcare systems. Advances in therapeutic technologies, such as focused drug delivery and minimally invasive tactics, pressure innovation in arachnoiditis remedy. Companies growing and commercializing technologically superior therapeutic answers gain a competitive gain in addressing the evolving needs of sufferers and healthcare companies. The aggressive panorama of the arachnoiditis market, characterized by the presence of more than one gamer, affects marketplace dynamics. Market competition drives businesses to differentiate their products and services, fostering innovation and enhancing standard patient care. Understanding and adapting to marketplace dynamics are critical for sustained fulfillment in this evolving landscape.
Arachnoiditis Market Highlights:
Arachnoiditis Market Scenario
The Arachnoiditis market is projected to reach USD 2.30 Billion by 2030 at 3.50% CAGR during the forecast period 2022-2030.
Arachnoiditis is a rare medical complication caused by damage or harm to the arachnoid layer of the spinal cord. The patient suffers from profound stinging, burning and neurological problems in this condition. Arachnoiditis is a result of unsuccessful surgery, the entrance of unwanted chemical in the spinal cord or viral and bacterial infection to the spinal cord. The growing geriatric population, an increasing number of surgeries, and technological advancement in the world is propelling the growth of the market. For instance, according to the United Nations, a population which is 60 or above 60-year-old is rapidly increasing and will reach 2.1 billion in 2050 from 936 million in 2017.
The rising cost of surgical procedures and treatments, stringent regulatory policies regarding approvals and scarcity of experts to treat arachnoiditis may hamper the growth of the market during the assessment period.
Segmentation
The arachnoiditis market has been segmented on the basis of type, cause, diagnosis, treatment, and end-user.
On the basis of type, the market has been classified as adhesive arachnoiditis, arachnoiditis ossificans, arachnoiditis ossificans, cerebral arachnoiditis, hereditary arachnoiditis, neoplastic arachnoiditis, and optochiasmatic arachnoiditis.
The market, by cause, has been segmented into trauma/surgery induced, chemically induced, and infection-induced. The trauma/surgery induced segment is divided into spinal surgery, lumbar puncture, spinal stenosis, and others. The chemically induced segment is further divided into myelograms and epidural steroid injection. The infection-induced segment is classified into viral and fungal meningitis, and tuberculosis.
The market on the basis of diagnosis is divided into CAT scan (computerized axial tomography), MRI (magnetic resonance imaging), and Electromyogram (EMG).
On basis of treatment, the market has been divided into Physical therapy, Pain medications, Nerve stimulation, and psychological support. Physical therapy segment is further divided into hydrotherapy, massage, and hot/cold therapy. lidocaine intravenous (IV) infusion, ketamine IV infusions, and naltrexone are part of pain medications. Nerve stimulation segment is divided into spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS).
The end user segment has been classified into hospital and clinics, pharmacies, diagnostic centers, and others.
The pain medication segment is likely to hold the first position in terms of market share and nerve stimulation will grow with the maximum growth rate.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The arachnoiditis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European arachnoiditis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The arachnoiditis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The arachnoiditis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Arachnoiditis Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The Americas are likely to dominate the arachnoiditis market owing to the favorable reimbursement policies, technological advancement and increasing number of surgeries in the region. For instance, in March 2017, FDA approved the new spinal surgery procedure named lumbar artificial disc replacement by activL artificial disc for the treatment of back pain
The European market is expected to be the second-largest arachnoiditis market. The market growth in this region can be attributed to the increasing geriatric population in the region, government initiatives and funding to the healthcare sector and increasing R&D activities. Moreover, a growing number of surgeries due to changing lifestyles is contributing to the growth of the market in this region.
Asia-Pacific is expected to be the fastest-growing arachnoiditis market during the forecast period owing to the increasing population, rising investments in healthcare, rising number of tuberculosis cases and expansions by market players in the region. According to the Global Tuberculosis Report 2017 published by the World Health Organization, Number Tuberculosis cases are significantly increasing and during the period 2013 to 2016, the number of new cases of tuberculosis were increased by 37%.
The market in the Middle East & Africa is expected to hold the smallest share of the arachnoiditis market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Key Players
Some of the key players in the arachnoiditis market are Baxter, B. Braun Melsungen AG, Pfizer Inc., SR Pharma, Abbott, AstraZeneca, Bristol-Myers Squibb Company, DuPont, Sandoz International GmbH, Takeda Pharmaceutical Company Limited, and Novartis AG.
Arachnoiditis Market, by Type Â
- Adhesive arachnoiditis
- Cerebral arachnoiditis
- Arachnoiditis ossificans
- Hereditary arachnoiditis
- Neoplastic arachnoiditis
- Optochiasmatic arachnoiditis
Arachnoiditis Market, by Cause
- Trauma/Surgery Induced
- Spinal Surgery
- Lumbar Puncture
- Spinal Stenosis
- Others
- Chemically Induced
- Myelograms
- Epidural Steroid Injection
- Infection-Induced
- Viral and Fungal Meningitis
- Tuberculosis
Arachnoiditis Market, by Diagnosis
- CAT scan (Computerized Axial Tomography)
- MRI (Magnetic Resonance Imaging)
- Electromyogram (EMG)
Arachnoiditis Market, by Treatment
- Physical Therapy
- HydrotherapyÂ
- Hydrotherapy
- Hot/Cold Therapy
- Pain Medications
- Lidocaine Intravenous (IV) Infusion
- Ketamine IV Infusions
- Naltrexone
- Nerve Stimulation
- Spinal Cord Stimulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Psychological Support
Arachnoiditis Market, by End User
- Hospital and Clinics
- Pharmacies
- Diagnostic Centers
- Others
Arachnoiditis Market, by Region
Americas
- North America
- US
- Canada
- South America
Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Middle East & Africa
- Middle East
- Africa
Company Profiles
- Baxter
- Braun Melsungen AG
- Pfizer Inc.
- SR Pharma
- Abbott
- AstraZeneca
- Bristol-Myers Squibb Company
- Sandoz International GmbH
- Du Pont
- Takeda Pharmaceutical Company Limited
- Novartis AGÂ
Intended Audience
- Healthcare Providers
- Pharmaceuticals Manufacturers
- Medical Device Manufacturers
- Research Institutes and Academic Centers
- Contract Research Organizations (CROs)
- Government Associations
- Market Research and Consulting
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
